Loading stock data…
Harrow (HROW)
$37.85-0.69 (-1.79%)
Market ClosedLast close Sep 8
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Harrow, Inc. in the Healthcare sector is trading at $37.85 with a market capitalization of $1.4B. Wall Street consensus targets $67.50 (8 analysts), implying a +78.3% move over the next 12 months. The stock is currently 31% below its 52-week high of $54.85, remaining 8.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +78.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $44.20M↓ | $89.09M↑ | $71.64M↑ | $63.74M↑ | $47.83M |
| Gross Profit | $27.05M↓ | $70.62M↑ | $53.93M↑ | $47.51M↑ | $32.31M |
| Operating Income | -$22.08M↓ | $15.59M↑ | $14.75M↑ | $11.41M↑ | -$11.23M |
| Net Income | -$27.60M↓ | $6.63M↑ | $1.02M↓ | $5.00M↑ | -$17.78M |
Peer Comparison
JNJUNHPFE
Fundamentals
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers Imprimis...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-52.12%
Volume
Today's trading volume
531,511
Recent News
This Fund Bought Moderna Before It Nearly Tripled. See Its 2 New Stock Picks
Bamco, the advisory arm of Ron Baron’s Baron Capital Group, opened a new position in Moderna (NASDAQ:MRNA) during the second quarter of 2026. The fund bought about 2 million shares of the firm in the June quarter. The timing worked out. In August, Moderna shares nearly tripled on a positive Phase 3 report. Bamco also […]
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target
On August 10, Harrow Inc. (NASDAQ:HROW) walked investors through a first half that fell short and a back half that now has to make up the difference. Revenue for the first six months of 2026 came in around $115 million, lighter than management had expected, largely because of pricing changes tied to VEVYE. Yet the […]
Harrow (HROW) Q2 2026 Earnings Call Transcript
Revenue hit $70.7M with guidance raised to $350M-$365M for full year.
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded via cash on hand, with up to $70 million in contingent […]
Harrow (HROW) Adds New Eye Care Firepower With Product Launch And Acquisition
Harrow (NasdaqGM:HROW) announced the launch of BYOOVIZ in the retinal biosimilar market, adding a new product to its ophthalmology lineup. The company reported expanded formulary coverage for VEVYE, increasing potential patient access to its dry eye disease treatment. Harrow acquired TYRVAYA, further building out its portfolio focused on dry eye disease. This cluster of product moves and acquisitions around eye care is part of a wider push across healthcare, and investors who follow Harrow...